BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 238 filers reported holding BLUEBIRD BIO INC in Q1 2021. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $49,503 | -9.8% | 16,284 | -2.4% | 0.00% | – |
Q2 2023 | $54,894 | -1.0% | 16,685 | -4.3% | 0.00% | – |
Q1 2023 | $55,424 | -41.8% | 17,429 | +26.7% | 0.00% | -100.0% |
Q4 2022 | $95,205 | +164.5% | 13,758 | +84.5% | 0.00% | – |
Q1 2022 | $36,000 | -52.0% | 7,458 | 0.0% | 0.00% | – |
Q4 2021 | $75,000 | -47.6% | 7,458 | 0.0% | 0.00% | -100.0% |
Q3 2021 | $143,000 | -40.2% | 7,458 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $239,000 | -7.0% | 7,458 | -12.5% | 0.00% | -50.0% |
Q1 2021 | $257,000 | -30.4% | 8,528 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $369,000 | -9.1% | 8,528 | +13.3% | 0.00% | -33.3% |
Q3 2020 | $406,000 | -11.5% | 7,524 | 0.0% | 0.00% | -25.0% |
Q2 2020 | $459,000 | +118.6% | 7,524 | +64.4% | 0.00% | +100.0% |
Q1 2020 | $210,000 | -37.1% | 4,576 | +20.1% | 0.00% | -33.3% |
Q4 2019 | $334,000 | -4.6% | 3,810 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $350,000 | -23.7% | 3,810 | +5.6% | 0.00% | -25.0% |
Q2 2019 | $459,000 | -23.8% | 3,609 | -5.7% | 0.00% | -20.0% |
Q1 2019 | $602,000 | +39.4% | 3,826 | -12.1% | 0.01% | +25.0% |
Q4 2018 | $432,000 | -27.3% | 4,353 | +7.0% | 0.00% | -20.0% |
Q3 2018 | $594,000 | -3.6% | 4,067 | +3.6% | 0.01% | 0.0% |
Q2 2018 | $616,000 | -3.4% | 3,924 | +5.0% | 0.01% | -16.7% |
Q1 2018 | $638,000 | +39.9% | 3,736 | +46.0% | 0.01% | +50.0% |
Q4 2017 | $456,000 | +124.6% | 2,559 | +72.8% | 0.00% | +100.0% |
Q3 2017 | $203,000 | +30.1% | 1,481 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $156,000 | -0.6% | 1,481 | -14.0% | 0.00% | 0.0% |
Q1 2017 | $157,000 | +18.0% | 1,723 | -19.9% | 0.00% | +100.0% |
Q4 2016 | $133,000 | -96.2% | 2,151 | -95.8% | 0.00% | -97.2% |
Q3 2016 | $3,481,000 | +61.6% | 51,362 | +3.2% | 0.04% | +28.6% |
Q2 2016 | $2,154,000 | +5.1% | 49,767 | +3.2% | 0.03% | +7.7% |
Q1 2016 | $2,049,000 | -21.6% | 48,218 | +18.6% | 0.03% | -21.2% |
Q4 2015 | $2,612,000 | -20.7% | 40,669 | +5.7% | 0.03% | -28.3% |
Q3 2015 | $3,292,000 | +19264.7% | 38,483 | +38771.7% | 0.05% | – |
Q2 2015 | $17,000 | +41.7% | 99 | 0.0% | 0.00% | – |
Q1 2015 | $12,000 | – | 99 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 4,282,827 | $13,019,794 | 1.84% |
Birchview Capital, LP | 455,200 | $1,383,808 | 1.18% |
PFM Health Sciences, LP | 6,040,934 | $18,364,439 | 0.86% |
Lion Point Capital, LP | 531,256 | $1,615,018 | 0.72% |
Endurant Capital Management LP | 251,785 | $765,426 | 0.69% |
Bleichroeder LP | 900,000 | $2,736,000 | 0.67% |
Connacht Asset Management LP | 31,634 | $96,167 | 0.57% |
Granahan Investment Management | 5,137,778 | $15,618,845 | 0.56% |
Frazier Life Sciences Management, L.P. | 1,709,907 | $5,198,117 | 0.34% |
Contrarius Investment Management Ltd | 1,308,002 | $3,976 | 0.22% |